title: Effects of topical antiglaucoma eye drops on prostaglandin E(2)-induced aqueous flare elevation in pigmented rabbits.
abstract: OBJECTIVE
  To evaluate the role of topical instillation of some antiglaucoma agents on experimental elevation of aqueous flare induced by prostaglandin E(2) (PGE(2)) in pigmented rabbits.
  
  
  METHODS
  Transcorneal diffusion of PGE(2) (25 microg/mL or 7.09 x 10(-2) mM) with the use of a glass cylinder was achieved to produce aqueous flare elevation in pigmented rabbits. An antiglaucoma agent was topically administered before application of PGE(2). Aqueous flare was measured with a laser flare cell meter.
  
  
  RESULTS
  A single instillation of apraclonidine 1.15%, two instillations of epinephrine 1.25%, two instillations of dipivefrin 0.1%, and two instillations and one instillation of dipivefrin 0.04% eye drops inhibited 98%, 96%, 87%, 73%, and 47% of PGE(2)-induced aqueous flare elevation, respectively. Timolol 0.5%, nipradilol 0.25%, dorzolamide 1%, and pilocarpine 2% eye drops had no effects on the increase of PGE(2)-induced flare.
  
  
  CONCLUSIONS
  Apraclonidine, epinephrine, and dipivefrin eye drops inhibit PGE(2)-induced elevation of aqueous flare in pigmented rabbits.
authors.affiliation: Department of Ophthalmology, Toyama Medical and Pharmaceutical University, Toyama, Japan. ophthal@ms.toyama-mpu.ac.jp
authors.forename: Yoriko
authors.initials: Y
authors.lastname: Hayasaka
authors.forename: Seiji
authors.initials: S
authors.lastname: Hayasaka
authors.forename: Xue-Yun
authors.initials: XY
authors.lastname: Zhang
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Nagaki
mesh_terms: D000287:Administration, Topical; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001082:Aqueous Humor / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D018916:Blood-Aqueous Barrier; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D015232:Dinoprostone / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005136:Eye Proteins / Q000378:metabolism; D005901:Glaucoma / Q000188:drug therapy; D008297:Male; D009883:Ophthalmic Solutions; D011817:Rabbits; D014606:Uveitis, Anterior / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*
chemical_list: D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D005136:Eye Proteins; D009883:Ophthalmic Solutions; C016986:apraclonidine; C015173:dipivefrin; D015232:Dinoprostone; D003000:Clonidine; D004837:Epinephrine